Table of Contents

1. Introduction
2. Key Serological Markers Of Hepatitis B
3. Hepatitis B Surface Antigen (HBsAg)
4. Hepatitis B Surface Antibody (anti-HBs)
5. Hepatitis B Core Antibody (anti-HBc)
6. Hepatitis B e Antigen (HBeAg)
7. Solutions by Joinstar
8. References

Introduction

Hepatitis B is a significant global health concern, with a substantial impact on liver health and overall morbidity. Understanding the serological markers of Hepatitis B is critical for diagnosis, monitoring, and therapeutic decision-making.

Key Serological Markers of Hepatitis B

Serological markers are essential in the diagnosis and management of Hepatitis B. There are several key markers that are routinely measured to assess infection status, immunity, and disease progression.

Hepatitis B Surface Antigen (HBsAg)

HBsAg is the primary marker of active Hepatitis B virus (HBV) infection. It is detectable in the blood 1-10 weeks after exposure to the virus and typically indicates an ongoing infection.

Quantitative Measure: Levels of HBsAg can exceed 100,000 IU/mL in chronic infections.

Hepatitis B Surface Antibody (anti-HBs)

Anti-HBs is an indicator of recovery and immunity following infection or successful vaccination. It appears after clearance of HBsAg and typically persists for life.

Quantitative Measure: A level of anti-HBs ≥10 mIU/mL is considered protective.

Hepatitis B Core Antibody (anti-HBc)

Anti-HBc appears at the onset of symptoms in acute Hepatitis B and persists for life. It indicates previous or ongoing infection.

Parameters: Total anti-HBc and IgM anti-HBc are measured, with IgM indicating recent infection.

Hepatitis B e Antigen (HBeAg)

HBeAg indicates active viral replication and high infectivity. It is used to monitor treatment efficacy and disease progression.

Quantitative Measure: HBeAg presence is a sign of active replication, whereas its absence and presence of anti-HBe suggest lower replication and infectivity.

Solutions by Joinstar

Joinstar provides a comprehensive range of diagnostic solutions for Hepatitis B, offering high sensitivity and specificity in the detection of HBV markers. These solutions are designed to enhance diagnostic accuracy and improve patient outcomes.

• HBsAg Detection: Joinstar offers assays with a sensitivity threshold of 0.05 IU/mL, allowing for early detection of active infection.
• Anti-HBs Quantification: Their tests provide precise quantification with results down to 2 mIU/mL, supporting accurate assessment of immunity.
• Anti-HBc Differentiation: Solutions by Joinstar include both total and IgM anti-HBc detection, facilitating acute versus chronic infection distinction.
• HBeAg and anti-HBe Testing: These tests are crucial for evaluating viral replication status and treatment response, with high specificity for e antigen markers.

References

1. World Health Organization. (2022). Hepatitis B. WHO Fact Sheets.
2. Centers for Disease Control and Prevention. (2021). Hepatitis B Screening and Testing Recommendations. CDC Guidelines.
3. Joinstar Biomedical Technology Co., Ltd. (2023). Diagnostic Solutions for HBV. Product Catalogue.
4. Seeger, C., Mason, W. S. (2020). Molecular Biology of Hepatitis B Virus Infection. Virology Journal.